Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03450343 · ClinicalTrials.gov registry record · Phase 1
Oral Azacitidine Plus Salvage Chemotherapy in Relapsed/Refractory Diffuse Large B Cell Lymphoma
A Phase 1 study, sponsored by Medical University of South Carolina.
- Completed
- Registry status
- Phase 1
- Development phase
- 9
- Enrollment target
NCT03450343 is a Phase 1 study that has completed, run by Medical University of South Carolina. The registered enrollment target is 9 participants.
The verdict
NCT03450343, a Phase 1 study, has completed, sponsored by Medical University of South Carolina.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 9 participants
- Enrollment target
Study Summary
The purpose of this study is to determine the safety and tolerability of adding oral azacitidine to the chemotherapy combination R-ICE. This study will also look at whether or not disease outcomes improve with the combination.
Interventions
- DRUG Oral azacitidine
- DRUG R-ICE
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 9 participants |
| Start Date | 2019-04-04 |
| Est. Completion | 2024-01-30 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03450343
The ClinicalTrials.gov registry entry for NCT03450343 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 9 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Medical University of South Carolina, which has 755 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Oral azacitidine is the first listed.
NCT03450343 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03450343 about?
NCT03450343 is a clinical study titled "Oral Azacitidine Plus Salvage Chemotherapy in Relapsed/Refractory Diffuse Large B Cell Lymphoma". The purpose of this study is to determine the safety and tolerability of adding oral azacitidine to the chemotherapy combination R-ICE. This study will also look at whether or not disease outcomes improve with the combination.
What is the current status of trial NCT03450343?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 9 participants. The study started on 2019-04-04. Estimated completion is 2024-01-30.
What interventions are being tested in trial NCT03450343?
The interventions under investigation include: Oral azacitidine (DRUG), R-ICE (DRUG).
Who is sponsoring clinical trial NCT03450343?
This trial is sponsored by Medical University of South Carolina, which has 755 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.